| Literature DB >> 33810374 |
Luigi Santacroce1,2,3, Michele Di Cosola4, Lucrezia Bottalico2, Skender Topi2,3, Ioannis Alexandros Charitos2, Andrea Ballini5,6, Francesco Inchingolo7, Angela Pia Cazzolla4, Gianna Dipalma7.
Abstract
This study is focused on the epidemiological characteristics and biomolecular mechanisms that lead to the development of precancerous and cancerous conditions of oral lesions related to Human Papilloma Virus (HPV) infections. Current evidence from the literature demonstrates the role of HPV in potentially malignant oral disorders. Therefore, the underlying biomolecular processes can give arise, or contribute to, benign lesions as well as to oral carcinogenesis.Entities:
Keywords: HPV; maxillary-facial surgery; oral cancer; oral carcinogenesis; oral infections; oral microbiota
Year: 2021 PMID: 33810374 PMCID: PMC8067023 DOI: 10.3390/v13040559
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.048
Figure 1Precursor conditions: infections, chronic mouth’s irritation, immune suppression and immune disorders (i.e., transplanted patients, due to the chronic inflammatory state associated with graft-versus-host disease (GVHD), lifestyle and environmental factors (e.g., alcohol abuse, tobacco smoking/chewing, betel quid or guṭkha chewing, marijuana, poor oral hygiene), low socio-economic status (poor or no access to oral health care facilities), dietary factors, radiation exposure, and genetic polymorphisms. (Adapted from [1]).
Figure 2This table relates the HPVs with the different degrees of risk for developing precancerous lesions or cancer (From WHO/IARC Agents Classified by the IARC Monographs, IARC Monographs on the identification of carcinogenic hazards to humans, until 2019).
Figure 3The oncogenic pathways of the HPV due to the activity of the viral oncoproteins E6 and E7 (Bak: Bcl-2 homologous antagonist/killer, FADD: Fas-associated protein with death domain, FLICE: procaspase 8, IAP-2: Interferon regulatory factor 3,CBP/300: CREB binding protein, TADA3: Transcriptional adaptor 3, Tyk2: tyrosine kinase 2).